eligibility_summary
Inclusion: CD20+ B‑cell NHL persistent/progressive after ≥2 systemic therapies, measurable disease, ECOG 0–1 or 2 with albumin >3.5, adequate hematologic/renal/hepatic/cardiac function, room‑air O2 ≥92%. Exclusion: prior CD20 gene‑modified cells, auto SCT <6 wks or any allo SCT, CNS lymphoma/disorder, significant infection/CV disease, HIV unless suppressed on ART, active HBV/HCV, other active cancers, primary immunodeficiency, pregnant/lactating, other barriers to participation.
trial_source
clinical_trials.gov from Dec 2, 2025
annotation_status
ai
ai_summary
Trial: Phase 1, first-in-human ACE1831 for relapsed/refractory CD20+ B‑cell malignancies. Interventions and mechanisms: - ACE1831: off-the-shelf, allogeneic gamma delta T-cell therapy conjugated to an anti‑CD20 antibody (cell therapy). The antibody directs gdT cells to CD20 on malignant B cells, enabling targeted T‑cell cytotoxicity. - Obinutuzumab (combination arm): type II anti‑CD20 monoclonal antibody that depletes B cells via direct cell death and immune effector functions (e.g., ADCC). - Cyclophosphamide and fludarabine: lymphodepleting chemotherapies to enhance gdT-cell persistence/engraftment. Cells/pathways targeted: - CD20 antigen on malignant B cells (DLBCL, FL, MZL, PMBCL, Burkitt, high‑grade). - Activation of gamma delta T-cell cytotoxic pathways against CD20+ cells. - Additional B‑cell depletion via anti‑CD20 mechanisms (obinutuzumab). Two arms: ACE1831 alone vs ACE1831 + obinutuzumab after lymphodepletion.